Online inquiry

IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13080MR)

This product GTTS-WQ13080MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MADCAM1 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_130760.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8174
UniProt ID Q13477
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ13080MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8425MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ3296MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ASN-1
GTTS-WQ9994MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA KD-247
GTTS-WQ4385MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-224818
GTTS-WQ9454MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IPH4102
GTTS-WQ15231MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA TAK-079
GTTS-WQ1977MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AGS-15E
GTTS-WQ14718MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SEG101
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW